Prostatic neoplasms Trials in Sutton, United Kingdom
Conditions / Prostatic neoplasms / Sutton, United Kingdom
Research into Prostatic neoplasms spans multiple therapeutic approaches and trial phases.
26 total trials for this combination
Showing top 10 of 26 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00638690 | Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | COMPLETED | PHASE3 |
| NCT00485303 | An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy | COMPLETED | PHASE2 |
| NCT02257736 | An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01522443 | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer | TERMINATED | PHASE3 |
| NCT02531516 | An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03767244 | A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03834506 | Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) | COMPLETED | PHASE3 |
| NCT04720157 | An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01605227 | Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 | COMPLETED | PHASE3 |
| NCT00036556 | Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer | COMPLETED | PHASE3 |